Publikation:

Mutational analysis of ProTx-I and the novel venom peptide Pe1b provide insight into residues responsible for selective inhibition of the analgesic drug target NaV1.7

Lade...
Vorschaubild

Dateien

Zu diesem Dokument gibt es keine Dateien.

Datum

2020

Autor:innen

Herzig, Volker
Vetter, Irina
Dekan, Zoltan
Gilchrist, John
Bosmans, Frank
Alewood, Paul F.
Lewis, Richard J.
King, Glenn F.

Herausgeber:innen

Kontakt

ISSN der Zeitschrift

Electronic ISSN

ISBN

Bibliografische Daten

Verlag

Schriftenreihe

Auflagebezeichnung

URI (zitierfähiger Link)
ArXiv-ID

Internationale Patentnummer

Angaben zur Forschungsförderung

Projekt

Open Access-Veröffentlichung
Core Facility der Universität Konstanz

Gesperrt bis

Titel in einer weiteren Sprache

Publikationstyp
Zeitschriftenartikel
Publikationsstatus
Published

Erschienen in

Biochemical Pharmacology. Elsevier. 2020, 181, 114080. ISSN 0006-2952. eISSN 1873-2968. Available under: doi: 10.1016/j.bcp.2020.114080

Zusammenfassung

Management of chronic pain presents a major challenge, since many currently available treatments lack efficacy and have problems such as addiction and tolerance. Loss of function mutations in the SCN9A gene lead to a congenital inability to feel pain, with no other sensory deficits aside from anosmia. SCN9A encodes the voltage-gated sodium (NaV) channel 1.7 (NaV1.7), which has been identified as a primary pain target. However, in developing NaV1.7-targeted analgesics, extreme care must to be taken to avoid off-target activity on other NaV subtypes that are critical for survival. Since spider venoms are an excellent source of NaV channel modulators, we screened a panel of spider venoms to identify selective NaV1.7 inhibitors. This led to identification of two novel NaV modulating venom peptides (β/μ-theraphotoxin-Pe1a and β/μ-theraphotoxin-Pe1b (Pe1b) from the arboreal tarantula Phormingochilus everetti. A third peptide isolated from the tarantula Bumba pulcherrimaklaasi was identical to the well-known ProTx-I (β/ω-theraphotoxin-Tp1a) from the tarantula Thrixopelma pruriens. A tethered toxin (t-toxin)-based alanine scanning strategy was used to determine the NaV1.7 pharmacophore of ProTx-I. We designed several ProTx-I and Pe1b analogues, and tested them for activity and NaV channel subtype selectivity. Several analogues had improved potency against NaV1.7, and altered specificity against other NaV channels. These analogues provide a foundation for development of Pe1b as a lead molecule for therapeutic inhibition of NaV1.7.

Zusammenfassung in einer weiteren Sprache

Fachgebiet (DDC)
570 Biowissenschaften, Biologie

Schlagwörter

Spider-venom peptide; Voltage-gated sodium channel; Electrophysiology; Tethered toxin; Peptide pharmacophore; Analgesic

Konferenz

Rezension
undefined / . - undefined, undefined

Forschungsvorhaben

Organisationseinheiten

Zeitschriftenheft

Zugehörige Datensätze in KOPS

Zitieren

ISO 690RUPASINGHE, Darshani B., Volker HERZIG, Irina VETTER, Zoltan DEKAN, John GILCHRIST, Frank BOSMANS, Paul F. ALEWOOD, Richard J. LEWIS, Glenn F. KING, 2020. Mutational analysis of ProTx-I and the novel venom peptide Pe1b provide insight into residues responsible for selective inhibition of the analgesic drug target NaV1.7. In: Biochemical Pharmacology. Elsevier. 2020, 181, 114080. ISSN 0006-2952. eISSN 1873-2968. Available under: doi: 10.1016/j.bcp.2020.114080
BibTex
@article{Rupasinghe2020-11Mutat-51661,
  year={2020},
  doi={10.1016/j.bcp.2020.114080},
  title={Mutational analysis of ProTx-I and the novel venom peptide Pe1b provide insight into residues responsible for selective inhibition of the analgesic drug target Na<sub>V</sub>1.7},
  volume={181},
  issn={0006-2952},
  journal={Biochemical Pharmacology},
  author={Rupasinghe, Darshani B. and Herzig, Volker and Vetter, Irina and Dekan, Zoltan and Gilchrist, John and Bosmans, Frank and Alewood, Paul F. and Lewis, Richard J. and King, Glenn F.},
  note={Article Number: 114080}
}
RDF
<rdf:RDF
    xmlns:dcterms="http://purl.org/dc/terms/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
    xmlns:bibo="http://purl.org/ontology/bibo/"
    xmlns:dspace="http://digital-repositories.org/ontologies/dspace/0.1.0#"
    xmlns:foaf="http://xmlns.com/foaf/0.1/"
    xmlns:void="http://rdfs.org/ns/void#"
    xmlns:xsd="http://www.w3.org/2001/XMLSchema#" > 
  <rdf:Description rdf:about="https://kops.uni-konstanz.de/server/rdf/resource/123456789/51661">
    <dc:creator>Rupasinghe, Darshani B.</dc:creator>
    <dc:contributor>Lewis, Richard J.</dc:contributor>
    <dc:language>eng</dc:language>
    <dc:creator>Vetter, Irina</dc:creator>
    <dc:creator>Herzig, Volker</dc:creator>
    <dc:contributor>Vetter, Irina</dc:contributor>
    <bibo:uri rdf:resource="https://kops.uni-konstanz.de/handle/123456789/51661"/>
    <foaf:homepage rdf:resource="http://localhost:8080/"/>
    <dc:creator>Dekan, Zoltan</dc:creator>
    <dc:creator>Lewis, Richard J.</dc:creator>
    <dcterms:available rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2020-11-05T08:52:16Z</dcterms:available>
    <dc:contributor>Rupasinghe, Darshani B.</dc:contributor>
    <dspace:isPartOfCollection rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/28"/>
    <void:sparqlEndpoint rdf:resource="http://localhost/fuseki/dspace/sparql"/>
    <dcterms:isPartOf rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/28"/>
    <dcterms:abstract xml:lang="eng">Management of chronic pain presents a major challenge, since many currently available treatments lack efficacy and have problems such as addiction and tolerance. Loss of function mutations in the SCN9A gene lead to a congenital inability to feel pain, with no other sensory deficits aside from anosmia. SCN9A encodes the voltage-gated sodium (Na&lt;sub&gt;V&lt;/sub&gt;) channel 1.7 (Na&lt;sub&gt;V&lt;/sub&gt;1.7), which has been identified as a primary pain target. However, in developing Na&lt;sub&gt;V&lt;/sub&gt;1.7-targeted analgesics, extreme care must to be taken to avoid off-target activity on other Na&lt;sub&gt;V&lt;/sub&gt; subtypes that are critical for survival. Since spider venoms are an excellent source of Na&lt;sub&gt;V&lt;/sub&gt; channel modulators, we screened a panel of spider venoms to identify selective Na&lt;sub&gt;V&lt;/sub&gt;1.7 inhibitors. This led to identification of two novel Na&lt;sub&gt;V&lt;/sub&gt; modulating venom peptides (β/μ-theraphotoxin-Pe1a and β/μ-theraphotoxin-Pe1b (Pe1b) from the arboreal tarantula Phormingochilus everetti. A third peptide isolated from the tarantula Bumba pulcherrimaklaasi was identical to the well-known ProTx-I (β/ω-theraphotoxin-Tp1a) from the tarantula Thrixopelma pruriens. A tethered toxin (t-toxin)-based alanine scanning strategy was used to determine the Na&lt;sub&gt;V&lt;/sub&gt;1.7 pharmacophore of ProTx-I. We designed several ProTx-I and Pe1b analogues, and tested them for activity and Na&lt;sub&gt;V&lt;/sub&gt; channel subtype selectivity. Several analogues had improved potency against Na&lt;sub&gt;V&lt;/sub&gt;1.7, and altered specificity against other Na&lt;sub&gt;V&lt;/sub&gt; channels. These analogues provide a foundation for development of Pe1b as a lead molecule for therapeutic inhibition of Na&lt;sub&gt;V&lt;/sub&gt;1.7.</dcterms:abstract>
    <dc:creator>King, Glenn F.</dc:creator>
    <dc:contributor>Dekan, Zoltan</dc:contributor>
    <dc:creator>Bosmans, Frank</dc:creator>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2020-11-05T08:52:16Z</dc:date>
    <dc:contributor>Herzig, Volker</dc:contributor>
    <dc:creator>Gilchrist, John</dc:creator>
    <dc:creator>Alewood, Paul F.</dc:creator>
    <dc:contributor>King, Glenn F.</dc:contributor>
    <dc:contributor>Gilchrist, John</dc:contributor>
    <dc:contributor>Alewood, Paul F.</dc:contributor>
    <dc:contributor>Bosmans, Frank</dc:contributor>
    <dcterms:issued>2020-11</dcterms:issued>
    <dcterms:title>Mutational analysis of ProTx-I and the novel venom peptide Pe1b provide insight into residues responsible for selective inhibition of the analgesic drug target Na&lt;sub&gt;V&lt;/sub&gt;1.7</dcterms:title>
  </rdf:Description>
</rdf:RDF>

Interner Vermerk

xmlui.Submission.submit.DescribeStep.inputForms.label.kops_note_fromSubmitter

Kontakt
URL der Originalveröffentl.

Prüfdatum der URL

Prüfungsdatum der Dissertation

Finanzierungsart

Kommentar zur Publikation

Allianzlizenz
Corresponding Authors der Uni Konstanz vorhanden
Internationale Co-Autor:innen
Universitätsbibliographie
Ja
Begutachtet
Ja
Diese Publikation teilen